Prevention of puerperal lactation with Parlodel long-acting (Parlodel LA).
Thirty women who did not want to breast-feed postpartum were treated with Parlodel LA. Immediately after birth 50 mg Parlodel LA were injected i.m. by means of a double-chamber syringe. The aim was to investigate in an open study the clinical efficacy and tolerability of Parlodel LA in the prevention of postpartum lactation. The overall efficacy was very good in 29 women (96.6%) and good in 1 woman (3.4%). In 27 women no symptoms of tenderness, engorgement or milk secretion were found (90%). In two cases slight and moderate mammary pain were reported during a few days, engorgement in only one case during one day and in three cases a slight milk let-down was seen for 1-2 days. In all cases the breast symptoms ceased spontaneously and no rebound lactation occurred in any of the women treated with Parlodel LA. The general tolerability was very good in 29 cases (96.6%) and good in one case (3.4%). No adverse effects were reported in any case. No obvious changes in blood pressure were noticed after the injection. In general a slight decrease occurred in systolic and/or diastolic blood pressure post-partum well within the range of non-treated healthy postpartum women. There were also no signs of orthostatic hypotension or changes in pulse rate accompanying the slight decrease in blood pressure. The local tolerability at the injection site was very good in 23 women (76.6%). Seven had short-lasting pain, slight in 6 cases and moderate in 1. Slight redness was reported in one case.(ABSTRACT TRUNCATED AT 250 WORDS)
D000293:Adolescent; D000328:Adult; D001971:Bromocriptine / Q000627:therapeutic use*; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007774:Lactation / Q000187:drug effects*; D049590:Postpartum Period; D011247:Pregnancy
D001971:Bromocriptine